September 27, 2021 | Featured
Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines
April 22, 2021 | Featured
Intract Pharma and NIBEC Enter into an Agreement to Develop a Novel Oral Peptide Therapy for Treatment of Ulcerative Colitis.
April 01, 2021 | Featured
Intract Pharma Enters into Research Collaboration with Ferring Pharmaceuticals to Evaluate Oral delivery of Monoclonal Antibodies for Treatment of Chronic Gastrointestinal Diseases
August 20, 2020 | Featured
Intract Pharma Limited and Celltrion Group announce collaboration for development of oral Infliximab.
Intract Pharma and N&S Pharmacy Investment announce partnership to develop orally-delivered GLP-1R agonist peptide therapeutic
Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics
January 29, 2020 | Events
Intract Pharma to Present at the 22nd BIO CEO & Investor Conference
October 24, 2019 | Featured
Intract’s Soteria® and Phloral® Technologies Highlighted Among Revolutionary Approaches to Crack Oral Biologics Delivery Challenge
Carus Animal Health and Intract Pharma Enter Agreement to Develop Novel Drug Delivery Technology
